12:00 AM
Apr 11, 2011
 |  BC Week In Review  |  Company News  |  Deals

Biogen Idec, Sunesis, Takeda deal

Biogen Idec divested two kinase inhibitor cancer programs to Takeda's Millennium Pharmaceuticals Inc. subsidiary as part of a restructuring announced last year. The programs, which were discovered under a 2004 deal with Sunesis, include an oral, selective pan-Raf kinase inhibitor slated to begin Phase I testing this year, and an undisclosed preclinical compound...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >